Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varespladib Methyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A known ✓ | P14555 | 18/20 | 0.83 |
| ▸ | PLA2G10 known ✓ | O15496 | 7/20 | 0.83 |
| ▸ | PLA2G5 known ✓ | P39877 | 5/20 | 0.83 |
| ▸ | PLA2G1B | P04054 | 6/20 | 0.83 |
| ▸ | PLA2G2E | Q9NZK7 | 6/20 | 0.83 |
| ▸ | PLA2G2F | Q9BZM2 | 4/20 | 0.83 |
| ▸ | PLA2G2D | Q9UNK4 | 4/20 | 0.83 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.83 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.83 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.83 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.83 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varespladib Methyl SCHEMBL29378302 | 1.00 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL818717 | 0.92 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5710708 | 0.91 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL6812616 | 0.91 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| Varespladib SCHEMBL29358982 | 0.91 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| Varespladib SCHEMBL26726 | 0.91 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5153686 | 0.91 | PLA2G2A (0.78) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL13632211 | 0.90 | PLA2G10 (0.84) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5710700 | 0.89 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL14620967 | 0.89 | PLA2G2A (0.66) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | claimed |
| US-20240382452-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX INC (US) | 2024-11-21 | — | — | US | claimed |
| CN-116585306-A | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| WO-2023086343-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-11-24 | — | — | US | claimed |
| CN-115379836-A | Early management and prevention of sepsis and sepsis-like syndrome | 奥菲瑞克斯公司 | 2022-11-22 | — | — | CN | claimed |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-10-20 | — | — | US | claimed |
| EP-4045026-A1 | EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES | Ophirex, Inc. (US) | 2022-08-24 | — | — | EP | claimed |
| EP-1950200-B1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | LILLY CO ELI (US) | 2012-01-11 | — | — | EP | claimed |
| EP-2395837-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | Anthera Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | claimed |
| US-20100160361-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | claimed |
| EP-2154958-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | Anthera Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | claimed |
| US-20090131396-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | claimed |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | ANTHERA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | claimed |
| WO-2008137803-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| EP-1950200-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | ELI LILLY AND COMPANY (US) | 2008-07-30 | — | — | EP | claimed |
| EP-1037630-A2 | METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2000-09-27 | — | — | EP | claimed |
| WO-1999024026-A2 | METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1999-05-20 | — | — | WO | claimed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | claimed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160361-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLAA, PLA2G3 | PLA2G2A 11/4885PLA2G10 18/4885PLA2G5 30/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 19/4885PLA2G10 9/4885PLA2G5 18/4885 |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | PLA2G12A, PLA2G3, PLA2G2E | PLA2G2A 15/4885PLA2G10 10/4885PLA2G5 26/4885 |
| US-20090131396-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLA2G3, PCSK9 | PLA2G2A 23/4885PLA2G10 10/4885PLA2G5 32/4885 |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 19/4885PLA2G10 8/4885PLA2G5 18/4885 |
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 14/4885PLA2G10 7/4885PLA2G5 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.